search
Back to results

Palliative Care for Patients With Dementia

Primary Purpose

Dementia

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Home Palliative Care
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Dementia

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: have advanced dementia, based on Global Deterioration Score (GDS)>6 impairment in at least one activity of daily living (ADL -which is inherent in this level of GDS) at least one hospitalization or ED visit within the last 12 months a physician who is primarily responsible for their dementia-related care whose clinical outpatient site is associated with one of the four Mount Sinai sites in Manhattan a family caregiver willing to enroll a residence in Manhattan where they are currently living (not in a long-term care facility) capacity to consent or a legal representative available to provide consent fluency in English or Spanish, or their legal representative must be fluent in English or Spanish age >64. Exclusion Criteria: Does not have a family caregiver to enroll Does not reside in Manhattan outside of long-term care facility Does not have fluency in English or Spanish Doesn't

Sites / Locations

  • Ichan School of Medicine at Mount SinaiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Palliative care at home

Augmented control

Arm Description

Randomized to intervention arm

Randomized to augmented control (visits to the caregiver from a CHW without training in dementia or palliative care)

Outcomes

Primary Outcome Measures

Symptom Management as measured by the End of Life for Dementia scale
This will be determined using a validated structured questionnaire administered to patient-subjects or caregiver via telephone interview or in person by the trained research coordinator. The Symptom Management at the End of Life in Dementia (SM-EOLD) scale responses range from 0 to 45 with higher scores indicating better symptom management.

Secondary Outcome Measures

Number of Hospital Admissions
Acute care utilization as measured by the number of hospital admissions
Number of Hospital Stays
Acute care utilization as measured by the number of hospital days
Patient reported treatment concordance
The Study Team will examine if the care patients receive is concordant with the care they wanted to receive using simple chart review of whether care received matches stated preferences (yes/no).
Cost Analysis
Total costs between the arms including inpatient, emergency department, ambulatory services, and home care services will be compared. Costs of the clinical intervention (e.g. clinical personnel, transportation) will be included in the analyses.
Caregiver burden per Zarit Burden Inventory
Zarit Burden Inventory to determine caregiver burden by using a validated structured 22-item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. Each item is on a 5-point scale range from 0 (never) to 4 (always). Full scale from 22 - 110, higher score indicates a greater burden.
Caregiver burden per Zarit Burden Inventory
Zarit Burden Inventory to determine caregiver burden by using a validated structured 22-item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. Each item is on a 5-point scale range from 0 (never) to 4 (always). Full scale from 22 - 110, higher score indicates a greater burden.
Caregiver satisfaction measured using FAMCARE-10
FAMCARE-10 to assess caregiver satisfaction by using a validated 10-item structured questionnaire administered to patient-subjects via telephone interview or in person by the trained research coordinator. Full scale ranges 0-20, with higher scores indicating higher satisfaction.
Caregiver satisfaction measured using FAMCARE-10
FAMCARE-10 to assess caregiver satisfaction by using a validated 10-item structured questionnaire administered to patient-subjects via telephone interview or in person by the trained research coordinator. Full scale ranges 0-20, with higher scores indicating higher satisfaction.
Caregiver depression measured by PHQ-9 Score
PHQ-9 to assess Caregiver Depression by using a validated structured 9 item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-27, with higher score indicating more severe symptoms.
Caregiver depression measured by PHQ-9 Score
PHQ-9 to assess Caregiver Depression by using a validated structured 9 item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-27, with higher score indicating more severe symptoms.

Full Information

First Posted
February 18, 2023
Last Updated
June 27, 2023
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT05749146
Brief Title
Palliative Care for Patients With Dementia
Official Title
Palliative Care at Home for Patients With Dementia and Their Caregivers
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 8, 2023 (Actual)
Primary Completion Date
April 2026 (Anticipated)
Study Completion Date
April 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A multi-site, single-blinded, parallel, randomized-controlled trial to evaluate the effectiveness of a novel model of in-home palliative care for dementia patients and their family caregivers. From inpatient and outpatient settings associated with four hospitals across New York City, patients with advanced dementia and their family caregivers will be randomized to intervention or augmented control.
Detailed Description
The objective of this randomized controlled trial is to study the impact of a new home based palliative care program on patients' symptoms, quality of life, satisfaction with care, completion of advance care planning documentation and receipt of care consistent with preferences. In addition, the study will examine the impact of this model of care on patient healthcare utilization, including hospitalization, emergency department utilization, and hospice use prior to death. The trial will also include patients' caregivers, in order to examine the impact of the intervention on caregiver burden and prevalence of depression. Patients randomized to the intervention will be scheduled for an intake visit. This visit will be undertaken by the team's registered nurse and/or social worker, together with a community health worker, and other team members (advanced practice nurse, MD), depending on patients' needs. Visits will combine a combination of video-teleconferencing technology and in person visits. Following this visit, and in conjunction with the nurse practitioner and/or MD, a care plan will be developed to address areas of clinical need highlighted during the intake visit. Patients in the intervention arm will receive ongoing monitoring and input (telephone-based, video-based, and in-person) from members of the clinical team, dependent on their identified needs. Patients' cases will be discussed at the weekly IDT meeting, as appropriate to the level of clinical need. Patients and caregivers will be provided with access to a 24 hour telephone line, staffed by a Mount Sinai based physician, which acts as an advice line out of hours. These physicians will be able to provide advice to patients and caregivers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects assigned to intervention or control arms in a 1:1 ratio
Masking
Outcomes Assessor
Masking Description
Single blind control
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Palliative care at home
Arm Type
Experimental
Arm Description
Randomized to intervention arm
Arm Title
Augmented control
Arm Type
Active Comparator
Arm Description
Randomized to augmented control (visits to the caregiver from a CHW without training in dementia or palliative care)
Intervention Type
Behavioral
Intervention Name(s)
Home Palliative Care
Intervention Description
Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Primary Outcome Measure Information:
Title
Symptom Management as measured by the End of Life for Dementia scale
Description
This will be determined using a validated structured questionnaire administered to patient-subjects or caregiver via telephone interview or in person by the trained research coordinator. The Symptom Management at the End of Life in Dementia (SM-EOLD) scale responses range from 0 to 45 with higher scores indicating better symptom management.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Number of Hospital Admissions
Description
Acute care utilization as measured by the number of hospital admissions
Time Frame
at 12 months
Title
Number of Hospital Stays
Description
Acute care utilization as measured by the number of hospital days
Time Frame
at 12 months
Title
Patient reported treatment concordance
Description
The Study Team will examine if the care patients receive is concordant with the care they wanted to receive using simple chart review of whether care received matches stated preferences (yes/no).
Time Frame
at 12 months
Title
Cost Analysis
Description
Total costs between the arms including inpatient, emergency department, ambulatory services, and home care services will be compared. Costs of the clinical intervention (e.g. clinical personnel, transportation) will be included in the analyses.
Time Frame
at 12 months
Title
Caregiver burden per Zarit Burden Inventory
Description
Zarit Burden Inventory to determine caregiver burden by using a validated structured 22-item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. Each item is on a 5-point scale range from 0 (never) to 4 (always). Full scale from 22 - 110, higher score indicates a greater burden.
Time Frame
at 6 months
Title
Caregiver burden per Zarit Burden Inventory
Description
Zarit Burden Inventory to determine caregiver burden by using a validated structured 22-item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. Each item is on a 5-point scale range from 0 (never) to 4 (always). Full scale from 22 - 110, higher score indicates a greater burden.
Time Frame
at 12 months
Title
Caregiver satisfaction measured using FAMCARE-10
Description
FAMCARE-10 to assess caregiver satisfaction by using a validated 10-item structured questionnaire administered to patient-subjects via telephone interview or in person by the trained research coordinator. Full scale ranges 0-20, with higher scores indicating higher satisfaction.
Time Frame
at 6 months
Title
Caregiver satisfaction measured using FAMCARE-10
Description
FAMCARE-10 to assess caregiver satisfaction by using a validated 10-item structured questionnaire administered to patient-subjects via telephone interview or in person by the trained research coordinator. Full scale ranges 0-20, with higher scores indicating higher satisfaction.
Time Frame
at 12 months
Title
Caregiver depression measured by PHQ-9 Score
Description
PHQ-9 to assess Caregiver Depression by using a validated structured 9 item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-27, with higher score indicating more severe symptoms.
Time Frame
at 6 months
Title
Caregiver depression measured by PHQ-9 Score
Description
PHQ-9 to assess Caregiver Depression by using a validated structured 9 item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-27, with higher score indicating more severe symptoms.
Time Frame
at 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: have advanced dementia, based on Global Deterioration Score (GDS)>6 impairment in at least one activity of daily living (ADL -which is inherent in this level of GDS) at least one hospitalization or ED visit within the last 12 months a physician who is primarily responsible for their dementia-related care whose clinical outpatient site is associated with one of the four Mount Sinai sites in Manhattan a family caregiver willing to enroll a residence in Manhattan where they are currently living (not in a long-term care facility) capacity to consent or a legal representative available to provide consent fluency in English or Spanish, or their legal representative must be fluent in English or Spanish age >64. Exclusion Criteria: Does not have a family caregiver to enroll Does not reside in Manhattan outside of long-term care facility Does not have fluency in English or Spanish Doesn't
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christian Espino
Phone
(212) 421-4632
Email
Christian.Espino@mssm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nathan Goldstein, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ichan School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Esspino
Phone
212-241-4632
Email
christian.espino@mssm.edu
First Name & Middle Initial & Last Name & Degree
Nathan Goldstein

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All of the individual participant data collected during the trial, after deidentification.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication.
IPD Sharing Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. For individual participant data meta-analysis. Proposals should be directed to christian.espino@mssm.edu. To gain access, data requestors will need to sign a data access agreement.

Learn more about this trial

Palliative Care for Patients With Dementia

We'll reach out to this number within 24 hrs